Last reviewed · How we verify

Nulibry — Competitive Intelligence Brief

Nulibry (FOSDENOPTERIN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cyclic Pyranopterin Monophosphate. Area: Neuroscience.

marketed Cyclic Pyranopterin Monophosphate Molybdenum cofactor biosynthesis protein 1 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Nulibry (FOSDENOPTERIN) — Sentynl Theraps Inc. Nulibry works by providing a functional molybdenum cofactor to cells, bypassing the genetic defect that causes molybdenum cofactor deficiency type A.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nulibry TARGET FOSDENOPTERIN Sentynl Theraps Inc marketed Cyclic Pyranopterin Monophosphate Molybdenum cofactor biosynthesis protein 1 2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cyclic Pyranopterin Monophosphate class)

  1. Sentynl Theraps Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nulibry — Competitive Intelligence Brief. https://druglandscape.com/ci/fosdenopterin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: